Latest & greatest articles for urinary tract infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on urinary tract infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on urinary tract infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for urinary tract infection

21. Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy

Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy | CADTH.ca Find the information you need Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy Last updated: February 15 (...) , 2019 Project Number: RA1013-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the comparative diagnostic accuracy of point-of-care urine dipstick testing versus microscopic urinalysis in adult patients who present urinary tract infections in the emergency room or primary care setting? Key Message One systematic review and twp non-randomized studies were identified regarding point-of-care urine dipstick testing for suspected urinary

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

22. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract (...) Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 26, 2019 Project Number: RC1101-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of urinary tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of urinary tract infections? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

23. Quantitative Results of a National Intervention to Prevent Hospital-Acquired Catheter-Associated Urinary Tract Infection: A Pre-Post Observational Study. Full Text available with Trip Pro

Quantitative Results of a National Intervention to Prevent Hospital-Acquired Catheter-Associated Urinary Tract Infection: A Pre-Post Observational Study. Many hospitals struggle to prevent catheter-associated urinary tract infection (CAUTI).To evaluate the effect of a multimodal initiative on CAUTI in hospitals with high burden of health care-associated infection (HAI).Prospective, national, nonrandomized, clustered, externally facilitated, pre-post observational quality improvement initiative (...) , for 3 cohorts active between November 2016 and May 2018.Acute care, long-term acute care, and critical access hospitals, including intensive care and non-intensive care wards.Target hospitals had a high burden of Clostridioides difficile infection plus central line-associated bloodstream infection, CAUTI, or hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infection, defined as cumulative attributable differences above the first tertile in the Targeted Assessment for Prevention

2019 Annals of Internal Medicine

24. Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last (...) updated: April 30, 2019 Project Number: RB1323-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of coated catheters compared to standard non-coated catheters for patients requiring long-term urinary catheter use for the prevention of urinary tract infections and blockage? What is the cost-effectiveness of coated catheters compared to standard non-coated catheters for patients requiring long-term

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

25. UroShield for preventing catheter-associated urinary tract infections

UroShield for preventing catheter-associated urinary tract infections UroShield for pre UroShield for prev venting catheter-associated enting catheter-associated urinary tr urinary tract infections act infections Medtech innovation briefing Published: 9 September 2019 www.nice.org.uk/guidance/mib191 pathways Sum Summary mary The technology technology described in this briefing is UroShield. It is used to prevent catheter-associated urinary tract infections (CAUTI) in people with long-term (...) -of-rights). Page 1 of 11reduce the average number of CAUTIs per patient per year. The available evidence does not currently confirm that this would be the case. The technology The technology UroShield (NanoVibronix) is a disposable ultrasound device designed to reduce the risk of catheter- associated urinary tract infection (CAUTI). It reduces bacterial colonisation and biofilm formation on indwelling urinary catheters. UroShield should not be used for treating an active urinary infection

2019 National Institute for Health and Clinical Excellence - Advice

26. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Full Text available with Trip Pro

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings.To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like

2019 Annals of Internal Medicine

27. Efficacy and safety of quinolones for the treatment of uncomplicated urinary tract infections in women: a network meta-analysis Full Text available with Trip Pro

Efficacy and safety of quinolones for the treatment of uncomplicated urinary tract infections in women: a network meta-analysis Efficacy and safety of quinolones for the treatment of uncomplicated urinary tract infections in women: a network meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting (...) of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Efficacy and safety of quinolones for the treatment of uncomplicated urinary tract infections in women: a network meta-analysis Alejandro G Gonzalez-Garay, Liliana Velasco-Hidalgo, Eric Ochoa-Hein, Roberto Rivera-Luna Alejandro G Gonzalez-Garay Instituto Nacional de Pediatria Corresponding Author ORCiD: https

2019 Research Square

28. Imipenem, cilastatin and relebactam (Recarbrio) - To treat complicated urinary tract and complicated intra-abdominal infections

Imipenem, cilastatin and relebactam (Recarbrio) - To treat complicated urinary tract and complicated intra-abdominal infections Drug Approval Package: RECARBRIO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: RECARBRIO Company: Merck Sharp & Dohme Corp. Application Number: 212819 Approval Date: 07/16/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling

2019 FDA - Drug Approval Package

29. Recurrent Uncomplicated Urinary Tract Infections in Women

factors for complicated UTI, as previously discussed, should also be elucidated. Patient history should document the symptoms the patient considers indicative of a UTI, the relationship of acute episode to infectious triggers (e.g. sexual intercourse), antimicrobials used for each episode, Copyright © 2019 American Urological Association Education and Research, Inc.® Recurrent Uncomplicated Urinary Tract Infection American Urological Association (AUA)/Canadian Urological Association (CUA)/ Society (...) Recurrent Uncomplicated Urinary Tract Infections in Women 1 Purpose Over the past few decades, our ability to diagnose, treat, and manage recurrent urinary tract infection (rUTI) long-term has evolved due to additional insights into the pathophysiology of rUTI, a new appreciation for the adverse effects of repetitive antimicrobial therapy (“collateral damage”), 1 rising rates of bacterial antimicrobial resistance, and better reporting of the natural history and clinical outcomes of acute

2019 American Urological Association

30. Pregnancy and lower urinary tract infection: opt for cefuroxime

Pregnancy and lower urinary tract infection: opt for cefuroxime Prescrire IN ENGLISH - Spotlight ''Pregnancy and lower urinary tract infection: opt for cefuroxime'', 1 April 2019 {1} {1} {1} | | > > > Pregnancy and lower urinary tract infection: opt for cefuroxime Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pregnancy and lower urinary tract (...) infection: opt for cefuroxime Requiring just a single dose, fosfomycin trometamol is easier to take than cefuroxime or the combination of amoxicillin + clavulanic acid, but less is known about its short-term effects on the unborn child exposed during the first trimester of pregnancy. It is wiser to choose cefuroxime as first-line treatment. Minor lower urinary tract infections are frequent during pregnancy. They are routinely treated because they are a risk factor for premature birth. The first-choice

2019 Prescrire

31. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. Full Text available with Trip Pro

Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. To evaluate the association between antibiotic treatment for urinary tract infection (UTI) and severe adverse outcomes in elderly patients in primary care.Retrospective population based cohort study.Clinical Practice Research Datalink (2007-15) primary care records linked to hospital episode statistics (...) and death records in England.157 264 adults aged 65 years or older presenting to a general practitioner with at least one diagnosis of suspected or confirmed lower UTI from November 2007 to May 2015.Bloodstream infection, hospital admission, and all cause mortality within 60 days after the index UTI diagnosis.Among 312 896 UTI episodes (157 264 unique patients), 7.2% (n=22 534) did not have a record of antibiotics being prescribed and 6.2% (n=19 292) showed a delay in antibiotic prescribing. 1539

2019 BMJ

32. Once-Daily Plazomicin for Complicated Urinary Tract Infections. Full Text available with Trip Pro

Once-Daily Plazomicin for Complicated Urinary Tract Infections. The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobacteriaceae.We randomly assigned 609 patients with complicated urinary tract infections (UTIs), including acute pyelonephritis, in a 1:1 ratio to receive intravenous plazomicin (15 mg per

2019 NEJM Controlled trial quality: predicted high

33. Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review Full Text available with Trip Pro

of this condition. , Glycosuria induced by SGLT2i, therefore, has been avidly researched in correlation with the infectious processes of the genito-urinary tract. Revision studies have shown an increase in the occurrence of genital infection in men and women using SGLT2i. , Regarding UTI's, some recent reviews have shown, based on trial analysis, that patients treated with SGLT2i may have a slightly increased risk of developing UTI. The results demonstrated in our study corroborate such analyzes. We compared (...) Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review Services on Demand Journal Article Indicators Cited by SciELO Related links Similars in SciELO Share Print version ISSN 0104-4230 On-line version ISSN 1806-9282 Rev. Assoc. Med. Bras. vol.65 no.2 São Paulo Feb. 2019 Review Article Use of sodium

2019 Revista da Associação Médica Brasileira

34. Urinary tract infections in women

with fever suggests pyelonephritis. Diagnosed using urine dipstick, microscopic urinalysis (bacteria, white blood cell, red blood cell), and urine culture. Antibiotic selection should be guided by local bacterial susceptibilities and guidelines, or based on known urine culture and sensitivity. Definition A urinary tract infection (UTI) is an infection of the kidneys, bladder, or urethra. Infectious cystitis is the most common type of UTI, which is caused by a bacterial infection of the bladder (...) Urinary tract infections in women Urinary tract infections in women - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Urinary tract infections in women Last reviewed: February 2019 Last updated: January 2019 Summary Can be clinically categorised into uncomplicated/complicated, acute, or recurrent. Escherichia coli is the most common organism in uncomplicated infections. Costovertebral angle tenderness together

2019 BMJ Best Practice

35. Vaccine Development for Urinary Tract Infections: Where Do We Stand? (Abstract)

Vaccine Development for Urinary Tract Infections: Where Do We Stand? Urinary tract infections (UTIs) are among the most common bacterial infections. Its management has become increasingly challenging due to antimicrobial resistance. The four mainstays to tackle this crisis rely on the development of new antibiotic agents, the introduction of preventive and alternative antimicrobial strategies, the concept of antimicrobial stewardship, and effective hygiene measures. One of the most effective (...) approaches to prevent UTIs is the design of a potent vaccine. OM-89 is a lyophilised preparation of membrane proteins from 18 different uropathogenic Escherichia coli strains. The safety and efficacy of this immunoactive agent is well documented; therefore, it is recommended for the prophylaxis of UTI according to the current European Association of Urology guidelines on urological infections. In terms of a true vaccine designed to target specifically pathogenic bacteria, no substance is currently

2019 European urology focus

36. Patient involvement in clinical trials: motivation and expectations differ between patients and researchers involved in a trial on urinary tract infections. Full Text available with Trip Pro

Patient involvement in clinical trials: motivation and expectations differ between patients and researchers involved in a trial on urinary tract infections. Patients should be involved in the design, conduct and dissemination of research that affects them. Patient involvement leads to empowerment and enhances the quality of research. Differing motives and expectations between researchers and patients involved can hamper involvement. We wanted to learn more about patients' and researchers (...) ' motives and expectations in order to improve the benefits of involvement for all parties. We implemented a patient board with ten patients and five researchers for a trial on urinary tract infections (UTIs). We asked each patient and researcher about his or her motivation and expectations regarding the patient board. We found that patients' motivations included the wish to improve the treatment of UTIs, to support patient involvement as a principle, and to enhance the benefit of others. Furthermore

2019 Research involvement and engagement Controlled trial quality: uncertain

37. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU

Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2019 Canadian Urological Association

38. Urinary tract infection (lower) - women

Urinary tract infection (lower) - women Urinary tract infection (lower) - women | Topics A to Z | CKS | NICE Search CKS… Menu Urinary tract infection (lower) - women Urinary tract infection (lower) - women Last revised in December 2019 A urinary tract infection (UTI) is usually caused by bacteria from the gastrointestinal tract, most commonlyEscherichia coli. Diagnosis Management Prescribing information Background information Urinary tract infection (lower) - women: Summary Lower urinary tract (...) infection (UTI) is an infection of the bladder (also known as cystitis) usually caused by bacteria from the gastrointestinal tract. Acute uncomplicated UTI usually resolves within a few days. Risk factors for complicated UTI include: Structural or neurological abnormalities. Pregnancy. Urinary catheterization. Atypical or resistant infecting organisms. Co-morbidities such as immunosuppression. Complications of lower UTI include pyelonephritis, impaired renal function, urosepsis and in pregnancy pre-term

2019 NICE Clinical Knowledge Summaries

39. Urinary tract infection (lower) - men

Urinary tract infection (lower) - men Urinary tract infection (lower) - men | Topics A to Z | CKS | NICE Search CKS… Menu Urinary tract infection (lower) - men Urinary tract infection (lower) - men Last revised in November 2018 Urinary tract infection (UTI) is infection of any part of the urinary tract, usually by bacteria. Diagnosis Management Prescribing information Background information Urinary tract infection (lower) - men: Summary Urinary tract infection (UTI) is infection of any part (...) of the urinary tract, usually by bacteria. The commonest uropathogen causing UTI in adults is Escherichia coli in approximately 80% of cases. UTI in men is generally uncommon, but incidence rates are higher in elderly men and those with risk factors, such as: Benign prostatic hypertrophy (BPH) and other causes of urine outflow obstruction (for example, urinary tract stones, urethral stricture). Catheterisation — UTI is the most common hospital acquired infection, and the majority of cases result from

2019 NICE Clinical Knowledge Summaries

40. Urinary tract infection - children

Urinary tract infection - children Urinary tract infection - children | Topics A to Z | CKS | NICE Search CKS… Menu Urinary tract infection - children Urinary tract infection - children Last revised in February 2019 Urinary tract infection (UTI) is illness caused by micro-organisms in the urinary tract. Diagnosis Management Prescribing information Background information Urinary tract infection - children: Summary Urinary tract infection (UTI) is illness caused by micro-organisms in the urinary (...) tract. Most UTIs are caused by bacteria from the gastrointestinal tract. Common organisms causing UTI in children include Escherichia coli (about 85% or more of cases), Klebsiella species, and Staphylococcus saprophyticus . Around 1 in 10 girls and 1 in 30 boys will have had a UTI by the age of 16 years. Overall, the prognosis after childhood UTI is good. However, in people with urinary tract comorbidity, progression of renal dysfunction is likely. Complications can include renal scarring

2019 NICE Clinical Knowledge Summaries